Plain-English translation of NCT07128680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a live bacterial supplement called EXL01, given alongside two immunotherapy drugs ( and ), can improve how well the treatment works for advanced kidney cancer. The bacteria in EXL01 may help your immune system fight the cancer more effectively. Researchers want to see if this combination is safe and whether it helps more than the standard two-drug treatment alone.
Immunotherapy drugs have helped many people with advanced kidney cancer, but not everyone responds well enough. Scientists believe that the bacteria living in your gut play a role in how well your immune system works, so adding a beneficial bacterial supplement might boost the cancer-fighting power of the existing medications.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the standard two immunotherapy drugs alone, or those same drugs plus the bacterial supplement taken by mouth daily. For the first 4 cycles (about 12 weeks), you'll receive IV infusions every 3 weeks, followed by ongoing treatment every 4 weeks. Throughout the study, you'll have regular CT scans and blood tests to monitor how you're responding and check for side effects. The trial is small—only about 33 people total—and you'll be followed closely by the research team at City of Hope Medical Center.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States